Corpusense

Johnson & Johnson (JNJ) earnings call transcript summary & sentiment

Last call Tue 13 Oct 2026

Our read on the 13 October 2026 earnings call

Overall tone: Positive

Overall tone

Positive

Executive Summary

Johnson & Johnson delivered third-quarter operational sales growth of 6.0% with revenue exceeding $25 billion, keeping the company on track to surpass $100 billion in annual revenue for the first time.

Core Signals

Revenue Growth & Demand: Third-quarter operational sales grew 6.0% year-over-year to over $25 billion, tracking ahead of consensus and pacing toward full-year revenue surpassing $100 billion.

Bullish Signals

Innovative Medicine operational sales increased 7.9% with eight distinct brands growing double digits, anchored by Oncology's 17% growth and Tremfya's 68% surge.

Risk Signals

Total MedTech operational growth slowed to 2.5%, missing internal management forecasts due to foreign market pressures and ongoing product headwinds.

Q&A Signals

Repeated analyst topics: Analysts repeatedly questioned MedTech's underperformance, the operational root causes and recovery timeline for Abiomed, and launch adoption dynamics for Icotide.

Key Investor Debate

The primary debate centers on whether MedTech's deceleration is transient or indicative of structural market share erosion in high-growth categories like pulsed field ablation (PFA) and heart recovery.

Analyst Takeaway

Management provided strong operational reassurance in Innovative Medicine with multiple clinical catalysts approaching, including Milvexian Phase III readouts and label expansions for Inlexo.

Those are the opening lines. The full read covers the whole earnings transcript: every bullish and bearish signal, what analysts pressed hardest on, and where management answered vaguely — each with the quote behind it. Every line sourced.

See the full Earnings Highlight

Themes across Johnson & Johnson and the Health Care sector

Analyse a theme over quarters — what's brand new, what's being talked about more, and what is spreading to more companies across the sector.

Unlock themes

Ask about Johnson & Johnson's earnings, or other S&P 500 earnings calls

Ask across the corpus, instead of reading one call at a time. Scope it to Johnson & Johnson, its sector, or every name we cover — plain English, no operators — and answers come back structured: a summary, the drivers, and a read on each company.

"What did Johnson & Johnson say about margins, and did the framing change from last quarter?"

"Did Johnson & Johnson's management walk back any full-year guidance, and how did they frame it?"

"Where did Johnson & Johnson avoid answering on capital allocation?"

Unlock search

Earnings call history & sentiment

Every one at 08:30 ET, before the open.

Date Day Period Corpusense read
2026-10-13Tuesday2026 Q4Positive
2026-07-15Wednesday2026 Q3Positive
2026-04-14Tuesday2026 Q2Positive
2026-01-21Wednesday2026 Q1—
2025-10-14Tuesday2025 Q4—
2025-07-16Wednesday2025 Q3—
2025-04-15Tuesday2025 Q2—
2025-01-22Wednesday2025 Q1—

Earnings calls across Pharmaceuticals, Biotechnology & Life Sciences - Smaller Industries

The companies Johnson & Johnson is read alongside. Each has its own earnings call dates and sentiment.

BMYBristol Myers SquibbLLYLilly (Eli)MRKMerck & Co.PFEPfizerVTRSViatrisZTSZoetis

Johnson & Johnson is one of the S&P 500 companies we track

Sentiment analysis on any single earnings call, themes building across a sector, and search across every company and quarter — each claim linked back to the passage it came from.

Create a free account See the full calendar Plans & pricing